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Abstract The purine analogs (PAs) cladribine and pentostatin
have transformed the prognosis of hairy cell leukemia (HCL).
However, some patients still relapse after PAs, or fail to reach
an optimal response, and new agents are needed to further
improve treatment outcome. We retrospectively studied 41
HCL patients from 10 centers in France and Belgium, who
received 49 treatment courses with the anti-CD20 monoclonal
antibody rituximab. Most of the patients were treated at re-
lapse (84 % of cases) and rituximab was combined to a PA in
41 % of cases. Overall, response rate is 90 % including 71 %
complete hematologic responses (CHRs). Frontline treatment,
combination therapy, and absolute neutrophil count were
associated with response in multivariate analysis. Three-year
relapse-free and overall survivals are 68 and 90 %, respective-
ly. When combined to a PA, rituximab yields a 100 % re-
sponse rate, even beyond frontline therapy. In contrast, re-
sponse rate is only 82 % (59 % CHR) when rituximab is used
alone. In this latter setting, relapse rate is 56 % and median
time to relapse is 17.5 months. All eight patients who were
treated two times with the antibody responded again to re-
treatment. We confirm the high efficacy of the combination
rituximab + PA. However, when rituximab is used as mono-
therapy, response rate is lower and the high relapse rate is a
concern. Prospective clinical trials are needed to confirm the
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superiority of the combination rituximab + PA over PA alone,
both as frontline therapy and at relapse.
Keywords Hairy cell leukemia . Rituximab .
Immunotherapy . Chronic leukemias
Introduction
Hairy cell leukemia (HCL) is a rare and indolent lymphoid
disorder, representing 2 % of all cases of lymphoid leukemias
[1]. It is characterized by the presence of mature leukemic
CD20-positive B cells showing both typical morphological
features and phenotypic profile and accumulating in the bone
marrow (BM), spleen, and liver. Hence, patients with HCL
usually present with cytopenias, splenomegaly, and some-
times hepatomegaly [2]. Treatment of HCL relies mainly on
the purine analogs (PAs) cladribine and pentostatin, which
have shown similar efficacy and constitute the gold standard
of care either as frontline therapy or for relapsed patients
[3–7]. However, despite the remarkable response rates obtain-
ed with PA therapy, some patients will eventually relapse and
the efficacy of these agents seems to decrease at each line of
treatment [5]. The addition of new molecules to PAs may
improve the response rates and prevent relapse.
Rituximab is a chimeric IgG1 kappa-type monoclonal
antibody directed against the CD20 molecule. It was
first used in relapsed patients with HCL more than
10 years ago [8], and several series of patients treated
with rituximab as monotherapy were published in the
following decade, reporting response rates ranging from
25 to 80 % [9–13]. These encouraging results have led
to combine rituximab with PA, both in previously un-
treated and in relapsed patients. As frontline therapy,
combination with cladribine provided an impressive
100 % response rate in two separate cohorts that in-
cluded a total of 63 patients [14, 15]. Moreover, mo-
lecular responses were obtained in 70 % of these pa-
tients. In the relapse setting, the efficacy of rituximab
combined with either cladribine, pentostatin, or even
fludarabine is also substantial with similar response
and relapse rates, even though the number of reported
patients is much lower [16, 17].
We designed a multicenter retrospective study of
patients treated with rituximab for HCL, either frontline
or at relapse and either in monotherapy or in combina-
tion with other molecules. The objectives of the study
were to assess the overall efficacy of rituximab in
distinct clinical settings from a cohort of unselected
patients representative of the population seen in the
routine practice, and to identify prognostic factors for
response, duration of response, and survival.
Methods
Patients
Patients were retrospectively recruited in 10 centers in France
and Belgium from July 2002 to September 2012. They were
eligible for inclusion in the study if they had a confirmed
diagnosis of classical HCL and had received at least three
subsequent injections of rituximab. No cases of HCL-variant
were included. Diagnosis of HCL relied on identification of
typical HCL cells in peripheral blood (PB) or BM with com-
patible immunophenotyping (diagnostic score of 3/4 or 4/4
according to Matutes et al. [18]) and/or immunochemistry.
Rituximab therapy
Rituximab was administered intravenously at the dose of
375 mg/m2 per injection in all patients but one who received
two infusions of 1,000 mg at day 1 and day 15 as induction
therapy and then a consolidation phase with the classic dos-
age. Patients were allowed to receive several treatment se-
quences with rituximab during the course of their disease.
Response assessment
Response to rituximab therapy was assessed during the first
6 months following the end of treatment, depending on avail-
able data. Complete hematologic response (CHR) was defined
as (i) the recovery of normal blood counts (absolute neutrophil
count (ANC) ≥1.5×109/L, hemoglobin level ≥120 g/L for
men and ≥110 g/L for women, and platelet count ≥100×109/
L) and (ii) the absence of circulating HCL cells and clinical
signs (mainly splenomegaly and hepatomegaly) of HCL; de-
pending on the availability of a BM assessment after rituxi-
mab therapy, CHR was further divided into three subgroups:
stringent complete response (sCR) if BM evaluation showed
no persistent leukemic cells, unconfirmed complete response
(uCR) if no BM trephine biopsy or aspirate was performed
after treatment, and CHR with persistent medullar infiltration
by leukemic cells (iCHR). Partial response (PR) was defined
as a ≥50 % improvement for every CHR-defining criterion or
normalization of at least one blood count (ANC, hemoglobin
level, or platelet count), without circulating HCL cells. Pa-
tients not meeting criteria for at least PR were classified as
non-responders (NR).
Relapse
Relapse was defined either by reappearance of HCL cells in
PB or BM or by a significant cytopenia (ANC ≤1.5×109/L,
hemoglobin level ≤110 g/L, or platelet count ≤100×109/L)
arising during follow-up, without other identifiable cause.
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Time to relapse was defined as the time between the first
rituximab infusion and relapse.
Minimal residual disease evaluation
Some patients included in this study had minimal residual
disease (MRD) evaluation after treatment. For these patients,
MRD was analyzed on a BM or PB sample using either
immunophenotyping by flow cytometry or detection of an
immunoglobulin heavy chain gene rearrangement by poly-
merase chain reaction (PCR) [19, 20].
Statistical analysis
Factors associated with treatment response were studied by
univariate analysis (the Student, Wilcoxon, Chi-square, or
Fisher’s exact tests, as appropriate) and by multivariate anal-
ysis (binary logistic regression with ascending stepwise selec-
tion and entry and exit thresholds set at 0.10). All variables
with a p value <0.10 by univariate analysis were included in
the multivariate analysis.
To assess potential predictive factors of relapse, univariate
(log-rank tests) and multivariate (Cox stepwise regression
with entry and removal limits set at 0.10) analyses were
performed. All variables with a p value <0.10 by univariate
analysis were included in the multivariate analysis.
Overall survival (OS) and relapse-free survival (RFS)
curves were estimated with the use of the Kaplan-Meier
method. For patients who received two separate treatment
sequences with rituximab, only the first one was included in
the statistical analyses of prognostic factors and survival.
A p value of 0.05 was considered statistically significant.
All analyses were performed with SAS® software, version 9.3
(SAS Inc, Cary, NC, USA).
Results
Patients’ characteristics
Forty-one patients were included in the study, for a total of 49
sequences of treatment with rituximab since eight of our
patients were treated two times with this agent.
Patients’ characteristics at time of rituximab therapy are
summarized in Table 1. Most of them (76 %) were males,
median age was 57 years, and one fifth was 70 or older. The
median time elapsed between diagnosis and initiation of ri-
tuximab therapy was more than 6 years (range 0–32 years).
Rituximab was used as part of frontline therapy in 16 % of
cases (8 of 49 treatments performed). For the 41 remaining
cases, the median number of previous therapeutic lines was 3
(range 1–8) with cladribine and pentostatin being the most
frequent previously used drugs (78 and 54 % of cases, respec-
tively). All these patients had received at least one PA, and in
32 % of cases, they had received both cladribine and
pentostatin. Other previous therapies included interferon in
20 cases (49 %), splenectomy in 7 cases (17 %),
norethandrolone in 1 case (2 %), and, as mentioned above,
rituximab in 8 cases (20 %).
For relapsed patients, overall response rate (ORR) to the
therapeutic line immediately preceding rituximab (which in-
cluded a PA in 76% of cases) was 87% (60 % CHR and 27%
PR).
Rituximab therapy
The median number of rituximab infusions per treatment
course was 4 (range 3–12).Most of the patients received either
four or eight infusions (65 and 15 % of cases, respectively).
Rituximab was used as monotherapy in 55 % of cases and in
combination with other agents in 45 % of cases. The most
frequently associated molecule was cladribine (18 of 22 cases,
82%), which was given either before (7 cases), concomitantly
(8 cases), or after rituximab administration (3 cases). In the
remaining cases, rituximab was combined with pentostatin
(two patients), interferon (one patient), and steroids (one pa-
tient). Rituximab was administered weekly in 88 % of cases
(among whom 23 % subsequently received additional infu-
sions at longer intervals). Median rituximab treatment dura-
tion was 24 days (range 14–695).
Rituximab was given because of disease relapse or pro-
gression (66 % of cases), contraindication to PA (12 %),
failure of previous therapeutic line (10 %), detectable MRD
after PA (10 %), and associated auto-immune hemolytic ane-
mia (2 %).
Table 1 Patients’ characteristics (n=41)
Sex ratio M/F 31/10
Age at diagnosis (median, range) 49 years (27–84)
Age at first rituximab infusion (median, range) 57 years (28–91)
Performance status 0/1 75.6 %/19.5 %
2/>2 4.9 %/0 %
B symptoms 8 (17 %)
Splenomegaly 4 (8.2 %)
Leukocytes (×109/L) (median, range) 2.1 (0.5–16.8)
Neutrophils (×109/L) (median, range) 1 (0.1–5.4)
Monocytes (×109/L) (median, range) 0.04 (0–0.6)
Hemoglobin (g/L) (median, range) 117.5 (50–169)
Platelets (×109/L) (median, range) 94 (21–386)
Presence of circulating HCL cells (% of cases) 39.1 %
M males, F females, HCL hairy cell leukemia
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Efficacy
Response assessment was available in 48 cases (Table 2).
Whatever treatment modalities (monotherapy or combina-
tion), ORR was 90 % (43 of 48 cases) and CHR was achieved
in 34 cases (71 %), including 6 sCRs (13 %), 26 uCRs (54 %),
and 2 iCHRs (4%). PR was observed in nine cases (19 %) and
treatment failure in five cases (10 %). Bone marrow evalua-
tion was done in only 14 cases (29 %), mostly by BM aspirate
(only three patients had a trephine biopsy), and was normal in
43 % of them.
All eight patients who received rituximab during frontline
therapy achieved a CHR (three sCRs and five uCRs), even
though it was combined with cladribine for five of them.
Regarding treatments given in relapsed patients, ORR was
88 % (including 65 % CHR and 23 % PR), with lower
response rates when rituximab was used as monotherapy (24
cases, ORR 79% and CHR 54%) than when it was combined
with cladribine or pentostatin (15 cases, ORR 100 %, CHR
86 %). Of note, all five treatment failures observed in this
study were relapsed patients treated with rituximab alone.
Overall, when rituximab was used in combination with a
PA (20 cases), ORR was 100 % (including 90 % CHR) versus
82 % (59 % CHR) when used as monotherapy (27 cases). No
significant association was found between the number of
administered rituximab infusions and the probability of re-
sponse to treatment; particularly, ORR for patients treated
with four infusions (90 %, including 71 % CHR) was compa-
rable to that of patients receiving more than four infusions
(93 %, including 73 % CHR).
Interestingly, all eight patients who had previously been
treated with rituximab responded to re-treatment with this
agent (6 uCRs, 1 iCHR, and 1 PR). Among them, five patients
even had a better response at re-treatment, although for only
one of them, rituximab was combined with a PA for this
second treatment course.
Five parameters correlated with the likelihood of achieving
a response to rituximab were identified by univariate analysis:
first-line treatment, combination therapy, ANC and platelet
count (with higher numbers increasing the probability of
achieving a response), and percentage of HCL cells in PB
before treatment (with lower numbers increasing the proba-
bility of achieving a response). Three independent factors
persisted after multivariate analysis: first-line treatment (odds
ratio (OR)=0.027, 95 % confidence interval (CI)=[0.001–
0.555], p=0.0192), combination therapy (OR=10.120, 95 %
CI=[1.227–83.485], p=0.0316), and high ANC before treat-
ment (OR=1.002, 95 % CI=[1.001–1.004], p=0.0060).
Nine patients had MRD evaluation after rituximab therapy,
which was performed by immunophenotyping in six cases
and by PCR in three cases. Two of them had undetectable
disease. Significant diminution ofMRDwas observed in three
additional cases, whereas three patients had stable MRD. The
last patient had a very low positive MRD after rituximab,
close to the detection threshold, but pre-treatment MRD was
not available.
Relapses and duration of response
Among the 43 responses observed after rituximab therapy
either alone or in combination, relapse or progression oc-
curred in 15 cases (35 %), after a median duration of
19 months (range 2–39) since the first rituximab infusion
(Table 2). Three-year RFS was 68 % (Fig. 1).
Regarding the eight patients who received rituximab during
frontline therapy (median follow-up 30.5 months, range 4–
76), only 1 (13 %) relapsed at 38 months. On the other hand,
when rituximab was used beyond frontline therapy (median
follow-up 38months, range 5–117), relapse rate was 40% and
median time to relapse was only 17.5 months (range 2–39).
Concerning the eight patients who were re-treated with ritux-
imab, five relapsed after this second treatment (63 %), at a
median of 30 months.
When rituximab was given alone, the relapse rate was as
high as 56 % compared to 14 % when used in combination
with another drug (only 11 % when the other drug was a PA).
Time to relapse was also shorter in case of monotherapy
(median 17.5 vs 38 months).
The only independent prognostic factors for relapse/
progression identified by multivariate analysis were platelet
Table 2 Response to treatment,
relapse rate, and duration of
response
R rituximab, PA purine analog,
ORR overall response rate, CHR
complete hematologic response,
mo months




Overall 48 90 71 35 26 (2–113)
1st line 8 100 100 13 30.5 (4–54)
R alone 3 100 100 0 40 (12–54)
R + PA 5 100 100 20 29 (4–38)
Relapse 40 88 65 40 23 (2–113)
R alone 24 79 54 63 23 (7–113)
R + PA 14 100 86 7 24.5 (10–79)
R + other 2 100 50 50 21 (2–40)
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infusion requirement before rituximab therapy (hazard ratio
(HR)=17.783, 95 % CI=[1.112–284.486], p=0.0419) and
hemoglobin level after treatment (with lower numbers increas-
ing the probability of relapse) (HR=0.943, 95 % CI=[0.892–
0.998], p=0.0406).
Overall survival
After a median follow-up of 36 months (range 4–117), 6 of 41
patients had died (15 %). Death occurred after a median of
37 months (range 9–76) since first rituximab infusion. Three-
year OS for the whole cohort was 90 % (Fig. 2). All of six
patients either did not respond to treatment or relapsed, except
one who died in remission.
Discussion
Whereas the largest series published to date concerns the use
of rituximab in combination with PA for frontline therapy of
HCL [14, 15], this situation represents only 5 of the 49
treatments reported in our study, with an excellent treatment
outcome (100 % CHR). Most of our patients were treated at
relapse, after multiple courses of therapy and a median time of
more than 6 years since HCL diagnosis. This can explain the
low incidence of splenomegaly, B symptoms, and severe
cytopenias at time of initiation of rituximab treatment. In this
relapse setting, the response rate we report (88 % ORR in-
cluding 65 % CHR) is satisfactory and equivalent to the one
observed at the previous line of therapy, even though combi-
nation to PA seems to provide a real benefit in this patient
Fig. 1 Relapse-free survival. Pts
patients, f/up follow-up
Fig. 2 Overall survival. Pts
patients, f/up follow-up
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population. There is scarce data available concerning the use
of frontline rituximab as monotherapy. Only four cases have
been reported to date and two of these patients have responded
to treatment [10, 21]. Here, we report three additional cases of
patients not eligible for frontline PA who received rituximab
alone. They all met uCR criteria and none of them had
relapsed after 12, 40, and 54 months of follow-up. Thus, this
treatment approach is feasible and might represent a good
alternative to interferon for patients who have contraindication
to PA, even though more data are needed to confirm our
results.
Another interesting issue that has not been assessed in the
literature is whether or not patients who have already received
rituximab for HCL may benefit from re-treatment with this
agent. In fact, only one case has been reported so far [22].
Eight of the 41 patients of our study were treated two times
with rituximab during the course of their disease. The re-
sponse rate at re-treatment is excellent (100 % ORR including
88 % CHR), and most surprisingly, five of these eight patients
had a better response to re-treatment as compared with first
treatment with rituximab, and none of them had a worst
response to re-treatment. Although the number of cases is
low, these results seem to support the possibility of multiple
rituximab therapy during the course of HCL, even in case of
non-optimal response to first treatment.
Despite the good response rate reported in our study, re-
lapse, which occurred in one third of our patients, remains a
concern, mostly when rituximab is used alone and beyond
frontline therapy. In this latter situation, the relapse rate we
observe (63 %) is higher than the ones previously reported in
the literature (ranging from 0 to 50 %) [9–13]. The longest
follow-up in our cohort (median 45 months for these patients)
may explain this difference. However, even in case of combi-
nation with PA, relapse rate in our study (11 % after a median
follow-up of 24.5 months) is still higher than published data,
although to a lesser extent [15, 16].
This study is the largest cohort of patients treated with
rituximab for HCL reported to date. The large inclusion
criteria we used have allowed us to study this molecule in
a wide range of clinical situations, some of which have
barely been explored in the literature. Most of all, our
patients are not selected patients for prospective clinical
trials but likely represent a good sample of the population
met in routine clinical practice. On the other hand, one
may argue that a limitation of this study is the wide
heterogeneity of our cohort. Additionally, our data do
not allow us to draw firm conclusions regarding the role
of rituximab for MRD eradication. In fact, only very few
patients had an MRD evaluation after treatment. More-
over, results are difficult to interpret because of the het-
erogeneity of the techniques and samples used for each
patient. The low rate of MRD negativity we observe after
rituximab (two of nine patients) may also be due to the
fact that MRD evaluation was often performed quite early
after treatment, whereas previously published data have
shown that molecular responses increase over time and
are still quite low at 2 and even 6 months [19, 14].
One of the limitations of this work may also concern
the choice of response criteria, which are slightly different
from the ones published in the guidelines from the British
Committee for Standards in Haematology [6]. In these
guidelines, response assessment and distinction between
PR and CR rely mainly on BM evaluation. However,
according to the recently published recommendations of
the French Society of Hematology for the management of
HCL patients [23], BM trephine biopsy evaluation after
treatment is not mandatory in France and is barely real-
ized outside prospective clinical trials. Indeed, in our
retrospective study, less than a third of patients had a
BM evaluation after rituximab therapy (and only three
had a BM trephine biopsy), making response assessment
incongruous in 70 % of cases regarding the British guide-
lines. Therefore, one should keep in mind that the
response rate we report may have been overestimated by
the criteria we used and the fact that most patients did not
have BM evaluation. On the other hand, as it has already
been shown that the optimal response may not occur
earlier than 2 or 3 months after treatment, response rate
may also have been underestimated in a few cases in
which response assessment was done too early because
of insufficient follow-up or missing data. We believe,
however, that the criteria we chose are well adapted to
routine clinical practice as they are based on the concept
of CHR, which is easy to assess. Another limitation of
this study is the relatively short median follow-up
(36 months) compared to other published series of
patients suffering from this chronic disease.
In conclusion, regarding the results of this and previous
studies, and before further data is available concerning the
efficacy and toxicity of BRAF inhibitors, we think rituximab
therapy for HCL should be considered either frontline, i.e., for
patients not eligible for treatment with a PA or not achieving
CR or negative MRD after PA, or at relapse, in combination
with a PA whenever possible given the high relapse rate and
short response duration when used as monotherapy. Random-
ized prospective studies are warranted to confirm the superi-
ority of the combination rituximab + PA over PA alone.
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